Your session is about to expire
← Back to Search
Retinoid
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
Phase 2
Waitlist Available
Led By Ervin Epstein, MD
Research Sponsored by UCSF Benioff Children's Hospital Oakland
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group
Summary
RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying topical tazarotene to see how well it works in treating patients with basal cell skin cancer and basal cell nevus syndrome on the face.
Eligible Conditions
- Neoplastic Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 36 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Complete Response Rate
Side effects data
From 2012 Phase 2 trial • 36 Patients • NCT0048908617%
erythema
17%
irritation
17%
dryness
11%
peeling
11%
rash
8%
itching
3%
edema
3%
prostate cancer diagnosis
3%
cellulitis and maxillary sinusitis
3%
inflammation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tazarotene Cream
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Tazarotene CreamExperimental Treatment1 Intervention
Open label
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tazarotene
FDA approved
Find a Location
Who is running the clinical trial?
UCSF Benioff Children's Hospital OaklandLead Sponsor
79 Previous Clinical Trials
19,015 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,956 Previous Clinical Trials
41,112,391 Total Patients Enrolled
6 Trials studying Neoplastic Syndrome
580 Patients Enrolled for Neoplastic Syndrome
Ervin Epstein, MDPrincipal InvestigatorUCSF Benioff Children's Hospital Oakland
5 Previous Clinical Trials
195 Total Patients Enrolled
David R. Bickers, MDPrincipal InvestigatorHerbert Irving Comprehensive Cancer Center
2 Previous Clinical Trials
34 Total Patients Enrolled